Check · IV therapy · IV vitamin drips In review

Do IV vitamin drips boost immunity, energy and hydration better than eating and drinking well?

Claim attributed to IV drip bars, med spas and concierge wellness clinics , This is the core marketing proposition of for-profit IV hydration bars, med spas and mobile and concierge services selling the "Myers' cocktail" and bespoke "Immunity", "Energy", "Hydration" and "hangover" drips. These are sellers with a direct commercial interest in the claim; their marketing pages are not evidence.

Verdict Unsupported

Evidence grade C Low certainty

The everyday wellness pitch does not hold up. The only placebo-controlled trial of the Myers' cocktail was null, the single positive vitamin-C trial helped only people who started depleted, and a replete body excretes the surplus within hours. Immunity and hydration are largely untested rather than disproven, but the comparative claim as marketed is unsupported.

It can spike a blood level for an afternoon and leave you a little poorer; in a well-fed body the surplus is in the urine by evening, and where the drip has been tested against a diet it has not won.

The theory

What it’s supposed to target

IV bioavailability
Vitamin C and B levels
Renal clearance
Hydration

The selling theory is bioavailability: swallowing vitamins caps how much you absorb, so infusing them into a vein reaches blood levels you cannot hit orally, supposedly supercharging immunity and energy. For a few nutrients this part is even true, IV can reach concentrations oral dosing cannot.

The flaw is what happens next. For water-soluble vitamins like C and the B group, the kidneys rapidly excrete the excess (the famous “expensive urine”), and in a well-nourished person there is no deficiency to fix and no evidence that transient high levels boost immunity. Mostly it is hydration plus a placebo-rich ritual: the bioavailability premise is real, the benefit it is meant to produce is not.

Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.

The claim

What would have to be true

Oral absorption would have to be the bottleneck in healthy people, so flooding the blood yields a durably higher tissue level. HOLDS POORLY: water-soluble vitamins are cleared by the kidneys within hours, and a replete body has nowhere to bank the surplus.

'Immunity' and 'energy' would have to be states a single micronutrient bolus measurably raises in someone already replete. NOT SHOWN: no validated endpoint and no high-quality trial demonstrates it; the one positive signal tracked relative depletion.

The flagship Myers' cocktail would have to beat placebo on a hard outcome. FAILS for its tested use: the one double-blind RCT was null between groups.

Benefit would have to outweigh the documented risks of placing a line and infusing non-physiological doses. NOT ESTABLISHED: independent reviews converge on no proven benefit alongside real, if uncommon, harm.

The evidence

What the evidence actually shows

The flagship trial was null, and the one positive trial only helped the depleted

The Myers' cocktail has been tested against placebo exactly once in a controlled trial: a double-blind, placebo-controlled pilot in 34 fibromyalgia patients, weekly IV infusions versus lactated Ringer's for eight weeks (34). On the primary outcome, the Tender Point Index, there was no significant difference between groups (p=0.60 at 8 weeks; p=0.39 at 12 weeks), and the authors' verbatim conclusion was that 'the efficacy of IVMT relative to placebo remains uncertain.' Both arms improved similarly within themselves - the signature of a placebo response, not an active drug, because the valid between-group test showed nothing. Notably this was independent NIH/NCCAM-funded work with no competing interests: independent money, null result. The strongest card for the other side is a double-blind RCT in 141 non-deficient office workers, where a single 10 g IV vitamin C lowered self-reported fatigue at two hours (p=0.004) (2). A fair reading defeats the marketing rather than supporting it: the benefit appeared only in participants with low baseline vitamin C (p=0.004) and not in those already adequate (p=0.206) - repletion of the depleted, not a universal lift. It was industry-linked (funded by the Korean Association for Vitamin Research, with two affiliated authors), unreplicated, and crucially never compared the drip against vitamin C by mouth.

Independent reviews converge on no proven benefit, plus real risk in an unregulated market

The bodies with no stake in selling drips line up. A 2023 Drug & Therapeutics Bulletin review found 'a lack of high-quality evidence to suggest that high-dose vitamin infusions are necessary or offer any health benefit in the absence of a specific vitamin deficiency or medical condition,' adding that injectable vitamins are prescription-only and 'should not be advertised to the public' (3). A 2025 narrative review in Cureus concluded the benefits claimed in healthy people are 'primarily anecdotal or based on self-reported outcomes rather than well-designed randomized clinical trials,' with 'insufficient scientific support' for general-wellness IV nutrient therapy - and catalogued the real risks: bloodstream infection and sepsis, fat-soluble vitamin (A/D/E/K) toxicity, fluid and electrolyte overload, phlebitis and vein damage, and anaphylaxis (4). Both note the 'Myers' cocktail' has no standard formulation, which makes rigorous trials hard. The setting compounds the problem: a 2025 JAMA Internal Medicine research letter found that, as of mid-2024, no US state or DC had legislation specifically regulating IV hydration spas, and only four states (Alabama, North Carolina, South Carolina, Vermont) addressed all key oversight aspects (7) - a structural gap that lets sellers market unproven drips with minimal safety oversight.

Evidence quality

Studies, graded, and who paid

The flagship 'Myers' cocktail' beats placebo for its tested indication C Low certainty

Tested once head-to-head and null: Ali 2009 found no between-group difference versus lactated Ringer's (p=0.60 at 8wk, p=0.39 at 12wk); both arms improved alike. For the one indication formally trialled, this is close to disproven.

A one-off vitamin bolus lifts energy in a non-deficient person C Low certainty

The lone positive RCT (Suh 2012) cut fatigue only in the LOW-baseline-vitamin-C subgroup (p=0.004), not in those already adequate (p=0.206). It supports correcting depletion, not 'beating food' in the replete - and never used an oral comparator.

An infusion boosts immunity or hydration better than eating and drinking D Very low certainty

No RCT in non-deficient people, no validated endpoint. Independent reviews (DTB 2023; Cureus 2025) find the wellness benefits anecdotal or self-reported. Unproven, not refuted - but unsupported by anything weighable.

Cited studies with type, size, funding/conflicts, and limitations.
#	Study	Type	Size	Funding / COI	Key limitations
34	Ali et al. 2009 - Myers' cocktail RCT (fibromyalgia)	Double-blind, placebo-controlled pilot RCT	34 randomized (16 infusion, 18 lactated-Ringer's placebo); 31 completed; weekly x8 weeks + follow-up to 12	Independent US NIH/NCCAM grants R21AT000942 and F32AT00667; authors declared no competing interests.	Tiny pilot; single condition; primary outcome null (between-group p=0.60 / 0.39); both arms improved similarly, consistent with placebo response.
2	Suh et al. 2012 - IV vitamin C and fatigue	Double-blind, placebo-controlled RCT	141 healthy office workers (70 vitamin C, 71 saline); single 10 g infusion	Industry-funded Korean Association for Vitamin Research; two authors held leadership/membership roles in the funding body (sponsor stated to have no role).	Subjective 0-10 endpoint; effect confined to LOW-baseline-vitamin-C subgroup (p=0.004) with none in adequate-baseline (p=0.206); single infusion, short follow-up; unreplicated; no oral comparator, so cannot test IV-vs-diet.
3	Drug & Therapeutics Bulletin 2023 - evidence review	Independent evidence review / editorial bulletin	Narrative review (no pooled n)	Independent Drug & Therapeutics Bulletin (BMJ), editorially independent, advertising-free; none declared.	Narrative, not a meta-analysis; reflects scarcity of primary trials rather than a pooled effect estimate.
4	Alangari 2025 (Cureus) - narrative review of IV vitamin therapy	Narrative review	Narrative review (no participants)	Independent Author declares no financial support, financial relationships or conflicts of interest.	Narrative, not a systematic review/meta-analysis; catalogues risks and the unstandardized formulations but pools no primary data.
7	CSPI/A4PC 2025 (JAMA Internal Medicine) - state oversight of IV hydration spas	Cross-sectional policy/regulatory analysis (research letter)	50 US states + DC (policy/practice survey)	Independent Center for Science in the Public Interest and Alliance for Pharmacy Compounding; published as a JAMA Internal Medicine research letter; no stake in selling drips.	Documents the regulatory gap, not clinical efficacy; policy snapshot as of mid-2024.

The funding pattern is the tell, and it runs opposite to the usual one. The independent money - the NIH-funded Myers'-cocktail trial, the BMJ and Cureus reviews - points away from benefit, while the one positive 'energy' trial was funded by a vitamin-research body and, on inspection, only moved a subjective score in the relatively depleted.

See who funded the studies behind every Caveat check

Stay neutral

Unproven ≠ disproven

Unproven is not disproven, and it cuts both ways. The immunity and hydration claims have essentially never been tested against a normal diet with validated endpoints, so they sit in unproven territory - not refuted, just unsupported by anything you could weigh; the one suggestive trial points to correcting low vitamin C, not boosting the replete.

The thinness is partly structural: IV wellness drips are unpatentable, cash-pay services sold at high margin, so there is little incentive to fund the large head-to-head trials that would settle 'better than food', and the endpoints sold - 'energy', 'immunity' - are vague and unvalidated.

The gap

Where claim and evidence diverge

The claim is comparative and durable - a drip beats eating and drinking well - but the evidence is, at best, conditional and route-blind. The flagship cocktail was null against placebo; the one positive energy signal corrected low baseline vitamin C, used a subjective score, and never included an oral comparator; immunity has no validated test at all.

So the gap is between a marketed superiority and a measured absence: where the claim has been examined against the alternative it names, it has not won.

Follow the funding

The money trail

IV drip bars, med spas and mobile and concierge services profit per infusion and per upsell from the very claim under review; their marketing pages are not evidence.

The strongest pro-claim trial (Suh 2012) was funded by the Korean Association for Vitamin Research, with two affiliated authors - and even then only helped the depleted; the null flagship trial (Ali 2009) was independently NIH-funded.

A 2025 JAMA Internal Medicine analysis flags this largely unregulated, profit-driven sector as a safety concern, with no state specifically regulating IV hydration spas as of mid-2024 (7).

Bottom line

The honest read

If you are genuinely deficient, or cannot eat, drink or absorb, IV nutrients are real medicine with a clear place. That is not what the drip-bar menu is selling: for a healthy, well-fed person the body is already topped up, the surplus from a spike is cleared by the kidneys within hours, and the one comparison the claim invites - a needle versus a diet - has not been won.

We grade this Unsupported rather than merely Unproven because the central claim is comparative and where it has been tested it has not won: the flagship cocktail was null, the one positive trial only helped the depleted, and independent reviews converge on no proven benefit plus real risk. The grade is C, not lower, in honest deference to how thin the direct disproof is - one small null RCT, one subgroup-confined positive, and mechanism, rather than a stack of large head-to-head wellness trials. The immunity and hydration promises are not disproven; they are unproven, and they are sold as if they were settled.

Falsifiable

What would change this verdict

A pre-registered, independently funded RCT in healthy, non-deficient adults showing a Myers'-cocktail-type drip produces a durable, clinically meaningful improvement on a validated immunity or energy endpoint versus saline placebo - and versus a matched oral dose.

Replicated evidence that the IV route delivers a lasting tissue advantage over an equivalent oral dose in replete people, contradicting the established saturation pharmacokinetics of water-soluble vitamins.

Receipts

Sources

Common questions